These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21661342)

  • 1. Bone-modifying agents in the treatment of advanced cancer.
    Ritchie KL
    S D Med; 2011 May; 64(5):167-8. PubMed ID: 21661342
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone targeted therapy in breast cancer: present and future.
    Huober J; Thürlimann B
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab for bone metastases.
    Med Lett Drugs Ther; 2011 Jan; 53(1356):8. PubMed ID: 21252843
    [No Abstract]   [Full Text] [Related]  

  • 4. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 5. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab for bone metastases from breast cancer: a new therapy option?
    Aapro MS
    J Clin Oncol; 2011 May; 29(14):e419-20; author reply e421-4. PubMed ID: 21464408
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventing metastases to bone: denosumab or bisphosphonates?
    Nanes MS
    J Bone Miner Res; 2010 Mar; 25(3):437-9. PubMed ID: 20200989
    [No Abstract]   [Full Text] [Related]  

  • 8. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
    Yoneda T
    Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
    Lipton A; Goessl C
    Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety considerations for use of bone-targeted agents in patients with cancer.
    Mortimer JE; Pal SK
    Semin Oncol; 2010 Jun; 37 Suppl 1():S66-72. PubMed ID: 20682374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm G
    Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bisphosphonates in the therapy of cancer patients].
    Jantunen E; Kumpulainen E
    Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857
    [No Abstract]   [Full Text] [Related]  

  • 13. Unravelling the role of denosumab in prostate cancer.
    Aragon-Ching JB
    Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
    [No Abstract]   [Full Text] [Related]  

  • 14. New strategies to prevent and manage bone complications in cancer.
    Lipton A
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):42-4. PubMed ID: 21326145
    [No Abstract]   [Full Text] [Related]  

  • 15. Denosumab and bisphosphonates: different mechanisms of action and effects.
    Baron R; Ferrari S; Russell RG
    Bone; 2011 Apr; 48(4):677-92. PubMed ID: 21145999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
    Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH;
    J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
    Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab findings in metastatic breast cancer.
    Stopeck A
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):159-60. PubMed ID: 20400929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.